Diversity of lipid mediators in human adipose tissue depots

American Journal of Physiology - Cell Physiology

Volumn 304, Issue 12, 2013, Pages

  Clària, Joan ^a   Nguyen, Binh T ^b   Madenci, Arin L ^b   Keith Ozaki, C ^b   Serhan, Charles N ^a  

^a Center for Experimental Therapeutics and Reperfusion Injury   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anti inflammatory and proresolving mediators; Vascular disease

Indexed keywords

15 HYDROXYICOSATETRAENOIC ACID; CD59 ANTIGEN; LEUKOTRIENE B4; LIPOXIN A; MARESIN 1; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROTECTIN 1; RESOLVIN D1; RESOLVIN D2; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ARTICLE; BODY MASS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LIPID STORAGE; LIPIDOMICS; LIQUID CHROMATOGRAPHY; METABOLOMICS; PRIORITY JOURNAL; SUBCUTANEOUS FAT; TANDEM MASS SPECTROMETRY;

ANTI-INFLAMMATORY AND PRORESOLVING MEDIATORS; VASCULAR DISEASE;

ADIPOSE TISSUE; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LIPID METABOLISM; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84879130007     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00351.2012     Document Type: Article

References (44)

1. Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, Gotlinger KH, Hong S, Serhan CN. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 174: 4345-4355, 2005.
2. Bohr S, Patel SJ, Sarin D, Irimia D, Yarmush ML, Berthiaume F. Resolvin D2 prevents secondary thrombosis and necrosis in a mouse burn wound model. Wound Repair Regen 21: 35-43, 2013.
3. Börgeson E, Docherty NG, Murphy M, Rodgers K, Ryan A, O'Sullivan TP, Guiry PJ, Goldschmeding R, Higgins DF, Godson C. Lipoxin A4 and benzo-lipoxin A4 attenuate experimental renal fibrosis. FASEB J 25: 2967-2979, 2011.
4. Börgeson E, McGillicuddy FC, Harford KA, Corrigan N, Higgins DF, Maderna P, Roche HM, Godson C. Lipoxin A4 attenuates adipose inflammation. FASEB J 26: 4287-4294, 2012.
5. Clària J, Dalli J, Yacoubian S, Gao F, Serhan CN. Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol 189: 2597-2605, 2012.
6. Duffield JS, Hong S, Vaidya VS, Lu Y, Fredman G, Serhan CN, Bonventre JV. Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol 177: 5902-5911, 2006.
7. Elks CM, Francis J. Central adiposity, systemic inflammation, and the metabolic syndrome. Curr Hypertens Rep 12: 99-104, 2010.
8. Ferrante AW Jr. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med 262: 408-414, 2007.
9. Filep JG. Resolution pathways in inflammation: the devil in the adipose tissues and in the details. Focus on "Diversity of lipid mediators in human adipose tissue depots." Am J Physiol Cell Physiol (March 6, 2013). doi:10.1152/ajpcell.00063.2013.
10. Flamand N, Mancuso P, Serezani CH, Brock TG. Leukotrienes: mediators that have been typecast as villains. Cell Mol Life Sci 64: 2657-2670, 2007.
11. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 316: 129-139, 2010.
12. González-Périz A, Horrillo R, Ferré N, Gronert K, Dong B, Moran-Salvador E, Titos E, Martínez-Clemente M, López-Parra M, Arroyo V, Clària J. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids. A role for resolvins and protectins. FASEB J 23: 1946-1957, 2009.
13. Hasturk H, Kantarci A, Goguet-Surmenian E, Blackwood A, Andry C, Serhan CN, Van Dyke TE. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol 179: 7021-7029, 2007.
14. Hellmann J, Tang Y, Spite M. Proresolving lipid mediators and diabetic wound healing. Curr Opin Endocrinol Diabetes Obes 19: 104-108, 2012.
15. Hellmann J, Tang Y, Kosuri M, Bhatnagar A, Spite M. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J 25: 2399-2407, 2011.
16. Horrillo R, González-Périz A, Martínez-Clemente M, López-Parra M, Ferré N, Titos E, Morán-Salvador E, Deulofeu R, Arroyo V, Clària J. 5-Lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J Immunol 184: 3978-3987, 2010.
17. Kim TH, Kim GD, Jin YH, Park YS, Park CS. Omega-3 fatty acid-derived mediator, resolvin E1, ameliorates 2,4-dinitrofluorobenzene-induced atopic dermatitis in NC/Nga mice. Int Immunopharmacol 14: 384-391, 2012.
18. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2: 612-619, 2001.
19. Liu G, Fiala M, Mizwicki MT, Sayre J, Magpantay L, Siani A, Mahanian M, Chattopadhyay M, La Cava A, Wiedau-Pazos M. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am J Neurodegener Dis 1: 60-74, 2012.
20. Mas E, Croft KD, Zahra P, Barden A, Mori TA. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 58: 1476-1484, 2012.
21. Mauro CR, Nguyen B, Yu P, Tao M, Gao I, Seidman MA, Nguyen LL, Ozaki CK. Inflammatory "adiposopathy" in major amputation patients. Ann Vasc Surg 27: 346-35, 2013.
22. Mauro CR, Ilonzo G, Nguyen B, Yu P, Tao M, Gao I, Seidman MA, Nguyen LL, Ozaki CK. Attenuated adiposopathy in perivascular adipose tissue compared to subcutaneous human adipose tissue. Am J Surg. doi:10.1016/j.amjsurg.2012.07.032. [Epub ahead of print]
23. Merched AJ, Ko K, Gotlinger KH, Serhan CN, Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 22: 3595-3606, 2008.
24. Norling LV, Spite M, Yang R, Flower RJ, Perretti M, Serhan CN. Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol 186: 5543-5547, 2011.
25. Odusanwo O, Chinthamani S, McCall A, Duffey ME, Baker OJ. Resolvin D1 prevents TNF-mediated disruption of salivary epithelial formation. Am J Physiol Cell Physiol 302: C1331-C1345, 2012.
26. Rajsheker S, Manka D, Blomkalns AL, Chatterjee TK, Stoll LL, Weintraub NL. Crosstalk between perivascular adipose tissue and blood vessels. Curr Opin Pharmacol 10: 191-196, 2010.
27. Sackmann-Sala L, Berryman DE, Munn RD, Lubbers ER, Kopchick JJ. Heterogeneity among white adipose tissue depots in male C57BL/6J mice. Obesity 20: 101-111, 2012.
28. Samuelsson B. Role of basic science in the development of new medicines: examples from the eicosanoid field. J Biol Chem 287: 10070-10080, 2012.
29. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-non-steroidal antiinflammatory drugs and transcellular processing. J Exp Med 192: 1197-1204, 2000.
30. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8: 349-361, 2008.
31. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LAJ, Perretti M, Rossi AG, Wallace JL. Resolution of inflammation: state of the art, definitions and terms. FASEB J 21: 325-332, 2007.
32. Serhan CN. Resolution phases of inflammation: novel endogenous anti-inflammatory and pro-resolving lipid mediators and pathways. Annu Rev Immunol 25: 101-137, 2007.
33. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M. Maresins: novel macrophage mediators with potent anti-inflammatory and pro-resolving actions. J Exp Med 206: 15-23, 2009.
34. Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol 177: 1576-1591, 2010.
35. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev 111: 5922-5943, 2011.
36. Tang Y, Zhang MJ, Hellmann J, Kosuri M, Bhatnagar A, Spite M. Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes 62: 618-627, 2013.
37. Thalmann S, Meier CA. Local adipose tissue depots as cardiovascular risk factors. Cardiovasc Res 75: 690-701, 2007.
38. Titos E, Rius B, González-Périz A, López-Vicario C, Morán-Salvador E, Martínez-Clemente M, Arroyo V, Clària J. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol 187: 5408-5418, 2011.
39. Trayhurn P. Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand 184: 285-293, 2005.
40. Wajchenberg BL, Giannella-Neto D, da Silva ME, Santos RF. Depotspecific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res 34: 616-621, 2002.
41. Wan M, Godson C, Guiry PJ, Agerberth B, Haeggström JZ. Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1. FASEB J 25: 1697-1705, 2011.
42. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210, 2008.
43. Wu SH, Chen XQ, Liu B, Wu HJ, Dong L. Efficacy and safety of 15(R/S)-methyl-lipoxin A4 in topical treatment of infantile eczema. Br J Dermatol 168: 172-178, 2013.
44. Yang R, Chiang N, Oh SF, Serhan CN. Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes. Curr Protoc Immunol 95: 14261-142626, 2011.